{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T09:52:34Z","timestamp":1777974754739,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"am","delay-in-days":333,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.canlet.2023.216287","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T02:06:20Z","timestamp":1688090780000},"page":"216287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Co-infusion of CAR T cells with aAPCs expressing chemokines and costimulatory ligands enhances the anti-tumor efficacy in mice"],"prefix":"10.1016","volume":"568","author":[{"given":"Jing","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weilin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinrong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maorong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengxi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuening","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feiyang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haozhan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7788-1895","authenticated-orcid":false,"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6165","key":"10.1016\/j.canlet.2023.216287_bib1","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.canlet.2023.216287_bib2","first-page":"166","article-title":"FDA approves fourth CAR-T cell therapy","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6382","key":"10.1016\/j.canlet.2023.216287_bib3","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.canlet.2023.216287_bib4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.imlet.2017.01.010","article-title":"CD19, from bench to bedside","volume":"183","author":"Li","year":"2017","journal-title":"Immunol. Lett."},{"issue":"20 Pt 1","key":"10.1016\/j.canlet.2023.216287_bib5","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"26","key":"10.1016\/j.canlet.2023.216287_bib6","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.canlet.2023.216287_bib7","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2023.216287_bib8","first-page":"559","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol"},{"issue":"1\u20132","key":"10.1016\/j.canlet.2023.216287_bib9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0022-1759(03)00010-3","article-title":"T cell stimulation and expansion using anti-CD3\/CD28 beads","volume":"275","author":"Trickett","year":"2003","journal-title":"J. Immunol. Methods"},{"issue":"57","key":"10.1016\/j.canlet.2023.216287_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd4344","article-title":"A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity","volume":"6","author":"Boulch","year":"2021","journal-title":"Sci Immunol"},{"issue":"4","key":"10.1016\/j.canlet.2023.216287_bib11","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood-2015-11-683847","article-title":"Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies","volume":"128","author":"Sabatino","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2023.216287_bib12","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3389\/fimmu.2018.02493","article-title":"Engineering CAR-T cells for improved function against solid tumors","volume":"9","author":"Morgan","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2023.216287_bib13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/imr.12129","article-title":"Human cell-based artificial antigen-presenting cells for cancer immunotherapy","volume":"257","author":"Butler","year":"2014","journal-title":"Immunol. Rev."},{"issue":"4","key":"10.1016\/j.canlet.2023.216287_bib14","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/PPO.0b013e3181eb33a6","article-title":"Artificial antigen-presenting cells for use in adoptive immunotherapy","volume":"16","author":"Turtle","year":"2010","journal-title":"Cancer J."},{"key":"10.1016\/j.canlet.2023.216287_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.omtm.2021.02.023","article-title":"Manufacturing NKG2D CAR-T cells with piggyBac transposon vectors and K562 artificial antigen-presenting cells","volume":"21","author":"Tay","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"11","key":"10.1016\/j.canlet.2023.216287_bib16","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2217\/imt-2018-0211","article-title":"Beta-2 microglobulin knockout K562 cell-based artificial antigen presenting cells for ex vivo expansion of T lymphocytes","volume":"11","author":"Zha","year":"2019","journal-title":"Immunotherapy"},{"issue":"5","key":"10.1016\/j.canlet.2023.216287_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064138","article-title":"Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells","volume":"8","author":"Singh","year":"2013","journal-title":"PLoS One"},{"issue":"72","key":"10.1016\/j.canlet.2023.216287_bib18","doi-asserted-by":"crossref","DOI":"10.3791\/50070-v","article-title":"Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood","author":"Huls","year":"2013","journal-title":"J. Vis. Exp."},{"issue":"8","key":"10.1016\/j.canlet.2023.216287_bib19","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.4049\/jimmunol.164.8.4025","article-title":"The CC chemokine CK beta-11\/MIP-3 beta\/ELC\/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells","volume":"164","author":"Braun","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2023.216287_bib20","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.biopha.2014.12.032","article-title":"CC motif chemokine ligand 19 suppressed colorectal cancer in vivo accompanied by an increase in IL-12 and IFN-\u03b3","volume":"69","author":"Lu","year":"2015","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.canlet.2023.216287_bib21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"12","key":"10.1016\/j.canlet.2023.216287_bib22","doi-asserted-by":"crossref","first-page":"6457","DOI":"10.4049\/jimmunol.171.12.6457","article-title":"EBV-induced molecule 1 ligand chemokine (ELC\/CCL19) promotes IFN-gamma-dependent anti-tumor responses in a lung cancer model","volume":"171","author":"Hillinger","year":"2003","journal-title":"J. Immunol."},{"issue":"25","key":"10.1016\/j.canlet.2023.216287_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd8936","article-title":"CD8(+) T cell immunity blocks the metastasis of carcinogen-exposed breast cancer","volume":"7","author":"Li","year":"2021","journal-title":"Sci. Adv."},{"issue":"20","key":"10.1016\/j.canlet.2023.216287_bib24","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-20-0777","article-title":"Coexpression of IL7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion","volume":"26","author":"Luo","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.canlet.2023.216287_bib25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.imbio.2014.03.003","article-title":"Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens","volume":"219","author":"Zeng","year":"2014","journal-title":"Immunobiology"},{"issue":"6","key":"10.1016\/j.canlet.2023.216287_bib26","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"issue":"11","key":"10.1016\/j.canlet.2023.216287_bib27","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1182\/blood-2007-09-113050","article-title":"IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy","volume":"111","author":"Hinrichs","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.canlet.2023.216287_bib28","doi-asserted-by":"crossref","first-page":"5902","DOI":"10.1038\/s41467-020-19672-2","article-title":"Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9","volume":"11","author":"Liu","year":"2020","journal-title":"Nat. Commun."},{"issue":"7786","key":"10.1016\/j.canlet.2023.216287_bib29","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.canlet.2023.216287_bib30","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1038\/cti.2014.16","article-title":"Stem memory T cells (TSCM)-their role in cancer and HIV immunotherapies","volume":"3","author":"Flynn","year":"2014","journal-title":"Clin Transl Immunology"},{"issue":"7918","key":"10.1016\/j.canlet.2023.216287_bib31","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-022-04801-2","article-title":"Potentiating adoptive cell therapy using synthetic IL-9 receptors","volume":"607","author":"Kalbasi","year":"2022","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.canlet.2023.216287_bib32","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1177\/1060028020944233","article-title":"Axicabtagene ciloleucel: clinical data for the use of CAR T-cell therapy in relapsed and refractory large B-cell lymphoma","volume":"55","author":"Halford","year":"2021","journal-title":"Ann. Pharmacother."},{"issue":"2","key":"10.1016\/j.canlet.2023.216287_bib33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.canlet.2023.216287_bib34","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2023.216287_bib35","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.canlet.2023.216287_bib36","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.mt.6300104","article-title":"Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma","volume":"15","author":"Park","year":"2007","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.canlet.2023.216287_bib37","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/mt.sj.6300134","article-title":"Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules","volume":"15","author":"Suhoski","year":"2007","journal-title":"Mol. Ther."},{"issue":"23","key":"10.1016\/j.canlet.2023.216287_bib38","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Anti-tumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.canlet.2023.216287_bib39","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.canlet.2023.216287_bib40","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/JLB.5MIR0917-351R","article-title":"IFN-\u03b3 orchestrates tumor elimination, tumor dormancy, tumor escape, and progression","volume":"103","author":"Aqbi","year":"2018","journal-title":"J. Leukoc. Biol."},{"issue":"6","key":"10.1016\/j.canlet.2023.216287_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"7897","key":"10.1016\/j.canlet.2023.216287_bib42","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.canlet.2023.216287_bib43","article-title":"Harnessing the chemokine system to home CAR-T cells into solid tumors","volume":"3","author":"Foeng","year":"2022","journal-title":"Cell Rep Med"},{"issue":"36","key":"10.1016\/j.canlet.2023.216287_bib44","doi-asserted-by":"crossref","first-page":"25855","DOI":"10.1074\/jbc.274.36.25855","article-title":"Distinct roles for STAT1, STAT3, and STAT5 in differentiation gene induction and apoptosis inhibition by interleukin-9","volume":"274","author":"Demoulin","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.canlet.2023.216287_bib45","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.4049\/jimmunol.2100764","article-title":"IL-2 signaling couples the MAPK and mTORC1 axes to promote T cell proliferation and differentiation in teleosts","volume":"208","author":"Mu","year":"2022","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.canlet.2023.216287_bib46","first-page":"523","volume":"139","author":"Funk","year":"2022","journal-title":"PI3K\u03b4\/\u03b3 inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. Blood"},{"issue":"4","key":"10.1016\/j.canlet.2023.216287_bib47","volume":"220","author":"Sun","year":"2023","journal-title":"STAT3 regulates CD8+ T cell differentiation and functions in cancer and acute infection. J Exp Med"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523002380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523002380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:09:35Z","timestamp":1759594175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383523002380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":47,"alternative-id":["S0304383523002380"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216287","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-infusion of CAR T cells with aAPCs expressing chemokines and costimulatory ligands enhances the anti-tumor efficacy in mice","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216287","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"216287"}}